Markets Are Getting Selective

Manufacturing Is Becoming Biotech’s Biggest Edge

Feruz Kurbanov

Senior Analyst

BeOne Medicines (6160.HK) recently announced that it will invest another $300 million to expand its manufacturing and research campus in New Jersey, bringing its total investment in the United States to more than $1 billion.

At first glance, this may look like a routine business decision to build more manufacturing capacity. However, when viewed alongside the many changes taking place across the biotechnology industry, the announcement tells us a much bigger story.

It reflects how pharmaceutical manufacturing has become increasingly important not only for business growth, but also for national competitiveness, supply chain security, quality of manufacturing, and the future of medical innovation.

The timing of this investment is particularly interesting because it comes as the U.S. Food and Drug Administration (FDA) is modernizing many of its manufacturing regulations.

Over the past several months, the FDA has introduced several initiatives designed to make it easier for companies to build and operate advanced manufacturing facilities while maintaining the same high standards for safety and quality.

Rather than lowering regulatory requirements, the agency is updating rules that were written decades ago for a very different era of medicine.

New technologies such as gene therapies, cell therapies, RNA medicines, and other advanced treatments require far more flexible and sophisticated manufacturing systems than traditional pharmaceutical factories.

One of the FDA’s current goals is to reduce unnecessary administrative burdens while encouraging companies to invest in modern manufacturing inside the United States.

Recent proposals to simplify facility registration, support advanced manufacturing networks, and improve communication with companies before new factories are built all point in the same direction.

The message is clear: the FDA wants to preserve rigorous scientific oversight while creating a regulatory system that better matches today’s rapidly evolving biotechnology industry.

Investments like BeOne’s suggest that companies are responding to these efforts by expanding their manufacturing capabilities in the United States.

Another reason this announcement is so significant is that BeOneMedicine has deep roots in China. Instead of concentrating all its manufacturing in Asia, the company is investing heavily in the United States.

That demonstrates an important shift in how global biotechnology companies think about growth. To become successful worldwide, companies increasingly need research, manufacturing, and commercial operations close to their largest target markets.

Building facilities in the United States provides access to one of the world’s largest healthcare markets, highly skilled workers, leading research institutions, and a well-established, globally leading regulatory system. Rather than choosing one country over another, many companies are building a global presence that allows them to compete internationally.

This also changes how we should think about the growing competition between the United States and China in biotechnology.

The competition is not simply about which country develops the next breakthrough medicine first. Instead, both countries are working to build complete biotechnology ecosystems that include scientific research, manufacturing, financing, regulation, and commercialization.

Healthy competition between these ecosystems is encouraging greater investment, faster innovation, and stronger global partnerships.

Manufacturing itself is becoming one of the industry’s most valuable competitive advantages. Having multiple manufacturing sites globally also builds resiliency into a business, and having those manufacturing sites close to the largest markets is always a logical approach.

Many of tomorrow’s medicines, including gene therapies, cell therapies, antibody-drug conjugates, bispecific antibodies, and RNA-based treatments, are far more difficult to manufacture than traditional small molecule drugs.

Producing these medicines safely, consistently, and at large scale requires specialized facilities, advanced technology, and highly trained workers.

Companies that master advanced manufacturing may gain an important advantage as these next-generation therapies move from clinical trials into widespread commercial use. This is one reason the FDA has devoted so much attention to modernizing manufacturing regulations over the past year.

When viewed together with the FDA’s recent regulatory reforms, the reopening of biotechnology capital markets, the increase in mergers and acquisitions, and the rapid growth of artificial intelligence in drug discovery, BeOne’s investment becomes much more than a factory expansion.

It is another sign that the biotechnology industry is entering a new stage of growth.

A Split Is Forming in the AI Infrastructure Race

Joe Withrow

Senior Analyst

A Chinese artificial intelligence (AI) startup called Moonshot AI recently released a new large language model (LLM) that its makers claimed rivaled the best systems from OpenAI and Anthropic. The market’s reaction was swift and brutal…

The VanEck Semiconductor ETF (SMH), which tracks the 25 largest semiconductor companies in the US, fell more than 4% in a single session. The ETF is still down roughly 20% from its June peak.

The fear was straightforward. If a scrappy startup can build a competitive model without the hundreds of billions of dollars in AI infrastructure spending that Nvidia, hyperscalers, and their supply chains have committed to, then maybe the entire capital-expenditure supercycle for AI infrastructure is overbuilt.

And if that was the case, it would stand to reason that every company selling into the AI buildout is currently overvalued.

This past week produced the first serious evidence that the market is starting to draw a more nuanced conclusion.

Barclays just raised its price target on Astera Labs (ALAB), a company that makes high-speed connectivity chips linking GPUs together inside AI data centers, to $325 from $200. That’s a 62% increase over the firm’s previous target.

And that wasn’t an isolated event. Bank of America and Susquehanna both materially raised their price targets on Credo Technology (CRDO), another AI-connectivity company. Meanwhile, the broader semiconductor index has done nothing but trade lower for a month.

This divergence signals to us that the market isn’t reconsidering whether AI infrastructure spending will happen. But it is scrutinizing which companies will capture the most value from that spending.

The reality is that, as AI models get more efficient, hyperscalers still will need to connect their GPUs using specialized technology. Larger clusters, which are now scaling toward hundreds of thousands of GPUs, make the interconnect fabric itself a primary bottleneck for utilization, reliability, power efficiency, and time-to-stability.

Broader industry forecasts reinforce the point. AI back-end networking and switch spending is projected to reach or exceed $100 billion by 2030. And the GPU interconnect market itself is expected to roughly double over the next five years.

In short, efficiency gains at the model layer do not eliminate the need for advanced copper and optical connectivity inside the data center. In some cases, efficiency gains may actually amplify the need for specialized technology.

The practical takeaway for investors is this…

The narrative that the AI infrastructure buildout is over-extended has been prevalent over the past few weeks. That aided a broad selloff in the stocks that had ridden the opposite narrative higher over the past few years.

I would suggest that view is too simplistic.

The market isn’t doubting the scale of the ongoing infrastructure buildout. It is simply starting to differentiate between the companies that supply essential technology to the build, and those that are minor players just riding the narrative.

That’s a healthier, more discriminating market than what we saw with the panic-selling of two weeks ago. But it’s also a reminder that broad sector ETFs and index-level narratives can obscure very different stories happening beneath the surface.

We should note that the companies that recover fastest from a sector-wide selloff are usually the ones with the most defensible, differentiated technology… and not necessarily the most obvious names.

A Lot for Markets to Process

Larry Benedict

Founder, The Opportunistic Trader

Markets have had plenty to digest over the past week, with investors juggling another Federal Reserve meeting and one of the most crucial earnings seasons we’ll see this year.

As expected, the Fed left interest rates unchanged. But the meeting wasn’t without surprises.

Three Fed officials dissented, instead favoring an immediate 0.25% hike. That highlights that inflation remains a major concern.

Kevin Warsh, as he outlined before taking over as chair, gave little away. He wants to keep the market’s focus on economic data rather than constantly trying to second-guess the Fed’s next move.

One thing is for sure: Markets are going to have to get used to less economic commentary from Warsh and other Fed officials than their predecessors.

On the earnings front, it’s been a mixed bag. On the one hand, last week we saw both Tesla and Amazon tank. But yesterday, Microsoft shot the lights out.

Overall, companies are producing solid results, but expectations remain incredibly high – that’s why stocks have been heavily punished for any disappointments.

Looking ahead, I’m not expecting markets to settle down or become any easier. As I said on Wednesday, I’m expecting a volatile second half of the year. U.S. Treasury yields have been climbing again. The U.S. 10-year yields again pushed through 4.7% this week.

Any increase in rate hike expectations is going to add another layer of pressure to the market.

And, of course, we never quite know how things will play out in the Middle East. Things can escalate sharply without any warning. We’ve seen how quickly renewed tensions can spill over into energy markets, inflation, and bond yields.

While it might make for an uncomfortable time for “buy and hold” investors, it’s the type of market where we traders can really put our mean reversion strategy to work.